Enhancing mechanisms associated with the degradation of misfolded proteins at the proteasome, that is, cellular structures where these proteins are degraded, may be a new therapeutic target for neurodegenerative diseases, including Parkinson’s disease. That’s according to a new study in fruit flies, where researchers found that the ZIP7 protein,…
The first 25 patients have been enrolled in a Phase 3 trial that’s testing the light-based, at-home therapy device called Celeste for treating Parkinson’s disease, its developer PhotoPharmics has announced. The “Celeste Light for PD Trial” is evaluating the device’s safety and effectiveness at easing both motor…
A newly developed molecule showed an ability in lab studies to activate antioxidant responses in brain cells by altering how two proteins, believed to be involved in the development of Parkinson’s disease and other neurodegenerative conditions, interact. The small molecule, known as a protein-like polymer, is designed to bind to…
Topline efficacy data from a Phase 3 clinical trial evaluating the oral therapy buntanetap for early-stage Parkinson’s disease is now expected in June, Annovis Bio, the therapy’s developer, has disclosed. While Annovis originally planned to share its early findings at the beginning of this year, the company faced…
Researchers in Canada have developed a new method to generate functional dopaminergic neurons, the dopamine-producing nerve cells lost in Parkinson’s disease, from human pluripotent stem cells (hPSC). The scientists used an antibody to selectively activate FZD5, a receptor, in the stem cells, which stimulated a specific molecular signaling pathway involved…
After adding $47 million in new funding, Cerevance is planning to launch a Phase 3 clinical trial to test its oral molecule CVN424, designed to treat people with early-stage Parkinson’s disease without the side effects seen with other therapies, the company announced in a press release. That…
People who carry a specific mutation in the RAB32 gene have a higher risk of developing Parkinson’s disease, researchers at the University of Florida found. The mutation, called RAB32 Ser71Arg, was identified in 16 individual families from different ethnic groups and increased the activation of the LRRK2 protein, a…
Cycling indoors on a stationary bicycle for two may improve the health and well-being of people with Parkinson’s disease and their care partners, a preliminary small study at the University of South Carolina suggests. The results were presented at the annual meeting of the American Academy of Neurology, which…
Rumble Boxing, a U.S. fitness brand, is partnering for the second year with Team Fox, the grassroots fundraising community of The Michael J. Fox Foundation (MJFF), to raise awareness and funds during Parkinson’s Disease Awareness Month this April. Among Rumble’s planned activities is a multicity tour panel…
The first patient has been dosed in a first-in-human trial testing Vanqua Bio’s VQ-101 as an oral therapy for Parkinson’s disease linked to mutations in the GBA gene, the company has announced. The Phase 1 clinical trial is assessing the safety, tolerability, and pharmacological properties of VQ-101 in both…
Get regular updates to your inbox.
